GLP-1

GLP-1 drugs like Ozempic, originally developed for diabetes and later weight loss, are now being tested in clinical trials for a widening range of conditions, including heart failure, addiction and even aspects of aging. The story highlights how quickly these medications are moving beyond their original use, with researchers exploring new therapeutic applications and observers debating how far the trend may go.

The Federal Reserve's latest Beige Book reports that GLP-1 weight-loss drugs such as Ozempic are changing consumer demand, with businesses noting reduced consumption of poultry and alcohol as users eat and drink less. The observation signals that the medications are now having measurable effects on the broader economy, not just the healthcare sector.

Blood sugar control is dominating Italian health news. A lab-made probiotic that produces GLP-1 and lowers glucose has been announced, while a Zurich implant reportedly burns blood sugar without medication. Other reports link medical stress to glucose spikes and stress the role of diet alongside GLP-1 drugs, as EU health officials push cardiovascular screening and prevention across member states.